Biogen Inc. (Nasdaq: BIIB) has released its 2023 Corporate Responsibility Report, illustrating the company’s strides in adhering to ethical business practices for the betterment of all stakeholders.
Christopher A. Viehbacher, President and CEO of Biogen, expressed pride in the company’s achievements over the past year. He emphasized Biogen’s commitment to pioneering scientific innovation for the benefit of patients and communities, while also generating value for shareholders. Viehbacher noted the refinement of Biogen’s corporate responsibility strategy in 2023, aimed at advancing evolving business priorities and maximizing positive impacts.
The report highlights progress across four main pillars:
- Access & Health Equity: Biogen expanded its medicine portfolio with four groundbreaking treatments and broadened access to SPINRAZA® for individuals with spinal muscular atrophy. The company also saw a notable increase in patients benefiting from tofersen through its Early Access Program. Furthermore, Biogen achieved significant success in meeting race and ethnicity enrollment targets in clinical trials.
- Workforce & DE&I: Biogen intensified its efforts in employee engagement, innovation, and fostering a culture of purpose. The company reported high levels of employee satisfaction, with 81% feeling a sense of purpose in their work. Additionally, Biogen highlighted progress in diversity, with nearly half of global leadership roles held by women and significant representation from diverse racial and ethnic backgrounds.
- Community Impact: Biogen continued its commitment to community welfare, refreshing its science education program to reach a wider audience under the new CoLab initiative. Through the Biogen Foundation, the company invested in addressing social determinants of health, including food security and healthcare access, providing substantial grants and meals to local communities. Employees also contributed over 10,000 volunteer hours.
- Environment: Biogen revamped its environmental strategy, focusing on efficiency improvements that yield both cost savings and environmental benefits. Notably, Biogen became the first major biotech company to certify all its labs through the My Green Lab program, recognized by the United Nations for sustainability. The company maintained its pledge to sourcing 100% renewable electricity and conducted multiple life cycle assessments to gauge product environmental impact.
The 2023 Corporate Responsibility Report aligns with globally recognized standards such as GRI, SASB, TCFD, and the UN Sustainable Development Goals (SDGs).
For further details on Biogen’s corporate responsibility efforts, the full report is available at http://www.biogen.com/esgreport.
About Biogen: Established in 1978, Biogen is a leading biotechnology firm dedicated to pioneering scientific breakthroughs for patient welfare and shareholder value. The company employs a diverse array of modalities to develop innovative treatments that deliver superior outcomes. Biogen’s strategy involves calculated risk-taking to ensure long-term growth and impact.
For additional investor information, visit www.biogen.com and follow Biogen on social media platforms including Facebook, LinkedIn, and YouTube.
Biogen Safe Harbor: This press release may contain forward-looking statements concerning various aspects of Biogen’s business, including strategy, commercial prospects, clinical programs, regulatory matters, and intellectual property. These statements are subject to inherent risks and uncertainties, and actual results may differ materially from those anticipated. Factors that could cause such discrepancies include market conditions, regulatory developments, clinical trial outcomes, and intellectual property challenges, among others. Biogen undertakes no obligation to update these forward-looking statements based on subsequent events or developments. For a comprehensive understanding of these risks, investors are advised to refer to Biogen’s filings with the U.S. Securities and Exchange Commission.
